SCHEMBL1859601

SCHEMBL1859601

S=C(Cc1ccc2c(c1)CCS2)N1CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
MGLL Q99685 5/20 0.53
FAAH O00519 3/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
CYP2C19 P33261 1/20 0.53
MAPT P10636 5/20 0.50
HPGD P15428 3/20 0.50
GAA P10253 2/20 0.50
APOBEC3G Q9HC16 1/20 0.50
NQO1 P15559 1/20 0.49
HTT P42858 1/20 0.36
NPC1 O15118 2/20 0.34
PKM P14618 2/20 0.34
RAB9A P51151 2/20 0.34
USP2 O75604 1/20 0.34
ALOX15 P16050 1/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12651582 0.79 ALDH1A1 (0.58) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL3920889 0.76 KMT2A (0.59) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL7950858 0.75 ALDH1A1 (0.55) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL14710213 0.74 MGLL (0.58) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL1984815 0.73 MGLL (0.53) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL15897524 0.72 MGLL (0.55) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL23048477 0.71 MGLL (0.65) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL4621432 0.71 MGLL (0.53) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL1987321 0.71 MGLL (0.56) ALDH1A1MGLLFAAHKMT2AMEN1
SCHEMBL6978893 0.70 ALDH1A1 (0.62) ALDH1A1MGLLFAAHKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015101928-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-09 WO disclosed
WO-2015101928-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS ROR GAMMA MODULATORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-09 WO disclosed
US-7935699-B2 Pyrazole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2011-05-03 US disclosed
EP-2261216-A2 Pyrazoles as glucokinase activators F. Hoffmann-La Roche AG (CH) 2010-12-15 EP disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 ALDH1A1 1567/4885MGLL 943/4885FAAH 3988/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.